The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations
COVID-19 is an infectious disease caused by the SARS COV-2 virus. Patients with COVID-19 are susceptible to thrombosis due to excessive inflammation, platelet activation, endothelial dysfunction, and circulatory stasis, resulting in an increased risk of death due to associated coagulopathies. In add...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Tropical Medicine and Infectious Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2414-6366/6/1/26 |
| _version_ | 1797396185751748608 |
|---|---|
| author | Sabina Karim Amin Islam Shafquat Rafiq Ismail Laher |
| author_facet | Sabina Karim Amin Islam Shafquat Rafiq Ismail Laher |
| author_sort | Sabina Karim |
| collection | DOAJ |
| description | COVID-19 is an infectious disease caused by the SARS COV-2 virus. Patients with COVID-19 are susceptible to thrombosis due to excessive inflammation, platelet activation, endothelial dysfunction, and circulatory stasis, resulting in an increased risk of death due to associated coagulopathies. In addition, many patients receiving antithrombotic therapy for pre-existing thrombotic diseases can develop COVID-19, which can further complicate dose adjustment, choice and laboratory monitoring of antithrombotic treatment. This review summarizes the laboratory findings, the prohemostatic state, incidence of thromboembolic events and some potential therapeutic interventions of COVID-19 associated coagulopathy. We explore the roles of biomarkers of thrombosis and inflammation according to the severity of COVID-19. While therapeutic anticoagulation has been used empirically in some patients with severe COVID-19 but without thrombosis, it may be preferable to provide supportive care based on evidence-based randomized clinical trials. The likely lifting of travel restrictions will accelerate the spread of COVID-19, increasing morbidity and mortality across nations. Many individuals will continue to receive anticoagulation therapy regardless of their location, requiring on-going treatment with low-molecular weight heparin, vitamin K antagonist or direct-acting anticoagulants. |
| first_indexed | 2024-03-09T00:46:41Z |
| format | Article |
| id | doaj.art-6d815a0e75284ad5a5d9141e44dae1f5 |
| institution | Directory Open Access Journal |
| issn | 2414-6366 |
| language | English |
| last_indexed | 2024-03-09T00:46:41Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Tropical Medicine and Infectious Disease |
| spelling | doaj.art-6d815a0e75284ad5a5d9141e44dae1f52023-12-11T17:27:29ZengMDPI AGTropical Medicine and Infectious Disease2414-63662021-02-01612610.3390/tropicalmed6010026The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management RecommendationsSabina Karim0Amin Islam1Shafquat Rafiq2Ismail Laher3Department of Paediatric Haematology and Oncology, National Institute of Cancer Research and Hospital, Mohakhali, Dhaka 1212, BangladeshMid and South Essex University Hospitals Group NHS Trust, Westcliffe on Sea, Prittlewell Chase SS0 0RY, UKDepartment of Gastroenterology, East Kent University Hospitals NHS Trust, Kennington Rd, Willesborough, Ashford TN24 0LZ, UKFaculty of Medicine, Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC V6T 1Z3, CanadaCOVID-19 is an infectious disease caused by the SARS COV-2 virus. Patients with COVID-19 are susceptible to thrombosis due to excessive inflammation, platelet activation, endothelial dysfunction, and circulatory stasis, resulting in an increased risk of death due to associated coagulopathies. In addition, many patients receiving antithrombotic therapy for pre-existing thrombotic diseases can develop COVID-19, which can further complicate dose adjustment, choice and laboratory monitoring of antithrombotic treatment. This review summarizes the laboratory findings, the prohemostatic state, incidence of thromboembolic events and some potential therapeutic interventions of COVID-19 associated coagulopathy. We explore the roles of biomarkers of thrombosis and inflammation according to the severity of COVID-19. While therapeutic anticoagulation has been used empirically in some patients with severe COVID-19 but without thrombosis, it may be preferable to provide supportive care based on evidence-based randomized clinical trials. The likely lifting of travel restrictions will accelerate the spread of COVID-19, increasing morbidity and mortality across nations. Many individuals will continue to receive anticoagulation therapy regardless of their location, requiring on-going treatment with low-molecular weight heparin, vitamin K antagonist or direct-acting anticoagulants.https://www.mdpi.com/2414-6366/6/1/26anticoagulantantiplateletantithrombotic therapyCOVID-19SARS-CoV-2thrombosis |
| spellingShingle | Sabina Karim Amin Islam Shafquat Rafiq Ismail Laher The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations Tropical Medicine and Infectious Disease anticoagulant antiplatelet antithrombotic therapy COVID-19 SARS-CoV-2 thrombosis |
| title | The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations |
| title_full | The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations |
| title_fullStr | The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations |
| title_full_unstemmed | The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations |
| title_short | The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations |
| title_sort | covid 19 pandemic disproportionate thrombotic tendency and management recommendations |
| topic | anticoagulant antiplatelet antithrombotic therapy COVID-19 SARS-CoV-2 thrombosis |
| url | https://www.mdpi.com/2414-6366/6/1/26 |
| work_keys_str_mv | AT sabinakarim thecovid19pandemicdisproportionatethrombotictendencyandmanagementrecommendations AT aminislam thecovid19pandemicdisproportionatethrombotictendencyandmanagementrecommendations AT shafquatrafiq thecovid19pandemicdisproportionatethrombotictendencyandmanagementrecommendations AT ismaillaher thecovid19pandemicdisproportionatethrombotictendencyandmanagementrecommendations AT sabinakarim covid19pandemicdisproportionatethrombotictendencyandmanagementrecommendations AT aminislam covid19pandemicdisproportionatethrombotictendencyandmanagementrecommendations AT shafquatrafiq covid19pandemicdisproportionatethrombotictendencyandmanagementrecommendations AT ismaillaher covid19pandemicdisproportionatethrombotictendencyandmanagementrecommendations |